Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SAR125844 |
Synonyms | |
Therapy Description |
SAR125844 is a selective inhibitor of MET, which inhibits MET activation and downstream pathway signaling, and potentially results in decreased growth of MET-driven tumors (PMID: 25504634, PMID: 29145039, PMID: 29108334). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAR125844 | SAR-125844 | MET Inhibitor 59 | SAR125844 is a selective inhibitor of MET, which inhibits MET activation and downstream pathway signaling, and potentially results in decreased growth of MET-driven tumors (PMID: 25504634, PMID: 29145039, PMID: 29108334). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01391533 | Phase I | SAR125844 | Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors | Completed | USA | ITA | FRA | ESP | 0 |
NCT02435121 | Phase II | SAR125844 | A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification | Completed | BEL | 0 |